Natural History of PRPF31 Mutation-Associated Retinal Dystrophy
What You Need to Know Before You Apply
What is the purpose of this trial?
The purpose of this study is to characterize the natural history through temporal systemic evaluation of subjects identified with PRPF31 mutation-associated retinal dystrophy, also called retinitis pigmentosa type 11, or RP11.Assessments will be completed to measure and evaluate structural and functional visual changes including those impacting patient quality of life associated with this inherited retinal condition and observing how these changes evolve over time.
Who Is on the Research Team?
Sreenivasu Mudumba, PhD
Principal Investigator
PYC Therapeutics
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Baseline Assessment
Initial assessments including ophthalmic exams, imaging studies, and electrophysiological testing
Follow-up
Participants are monitored for changes in visual function and retinal structure every 16 weeks for the first year and every 24 weeks for up to 4 years
What Are the Treatments Tested in This Trial?
Interventions
- None
Find a Clinic Near You
Who Is Running the Clinical Trial?
PYC Therapeutics
Lead Sponsor